#STAT1
On JHI's November issue cover (rupress.org/jhi/issue/2/6): Circos plots reveal reduced predicted inflammatory cross-talk from #monocytes to other peripheral blood mononuclear cells during JAK-inhibitor treatment in two #STAT1 gain-of-function patients. Iglesias-Herrero et al. doi.org/10.70962/jhi...
November 2, 2026 at 3:06 PM
@jhumimmunity.org's Nov. cover (rupress.org/jhi/issue/2/6): Circos plots reveal reduced predicted inflammatory cross-talk from #monocytes to other peripheral blood mononuclear cells during JAK-inhibitor treatment in two #STAT1 gain-of-function patients. Iglesias-Herrero et al doi.org/10.70962/jhi...
November 2, 2026 at 4:31 PM
Dianshan Ke et al. propose that targeted interventions aimed at enhancing STAT1 phosphorylation may serve as a promising therapeutic strategy for osteoclastogenic bone loss. Read the article in Differentiation to learn more: https://www.sciencedirect.com/science/article/pii/S0301468126000721
October 30, 2026 at 9:05 PM
Single-cell profiling quantifies the dose gap between population-average and complete pY-STAT1/3 suppression by JAK inhibitors https://www.biorxiv.org/content/10.64898/2026.10.26.759076v1
October 28, 2026 at 1:01 PM
Single-cell profiling quantifies the dose gap between population-average and complete pY-STAT1/3 suppression by JAK inhibitors https://www.biorxiv.org/content/10.64898/2026.10.26.759076v1
October 28, 2026 at 1:01 PM
Single-cell profiling quantifies the dose gap between population-average and complete pY-STAT1/3 suppression by JAK inhibitors #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.10.26.759076v1
October 28, 2026 at 2:01 PM
Oxidative Stress Potentiates a STAT1-APOL1 Feedforward Loop and Governs Disease Severity in APOL1-Mediated Kidney Disease pubmed.ncbi.nlm.nih.gov/42901322/
October 21, 2026 at 9:01 AM
Incidentally is their any way this can be an honest mistake? They are picking up something STAT3 off-target (STAT1, STAT5) and just being really careless?
October 21, 2026 at 12:25 PM
Endothelial signaling contributes to liver metastatic colonization.

This study identifies an exosomal RN7SL2–STAT1–KLF4 axis that remodels chromatin accessibility and superenhancers to promote #Cancer cell #Metastasis. #ExosomeBiology

#STTT #OpenAccess: doi.org/10.1038/s413...
October 21, 2026 at 4:02 PM
This study links macrophage dysferlin to Ca²⁺-dependent STAT1-associated inflammatory responses and impaired myogenic differentiation in cellular models. www.life-science-alliance.org/content/9/12...
October 17, 2026 at 3:04 PM
Viral infection activates the IRF1-BAK axis to drive mitochondria-derived inflammation
Viral infection activates the IRF1-BAK axis to drive mitochondria-derived inflammation
Ye et al. reveal that BAK is an interferon-stimulated gene up-regulated by the STAT1-IRF1 axis during viral infection, which induces mitochondria-derived inflammation. This mechanism is utilized by RNA and DNA viruses and underlies inflammatory diseases.
dlvr.it
October 17, 2026 at 12:35 PM
JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in #STAT1 gain-of-function. New study from Cecilia Iglesias-Herrero, Rik Schrijvers (KU Leuven) and colleagues:
rupress.org/jhi/article/...

#InbornErrorsOfImmunity
October 16, 2026 at 3:15 PM
Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1 https://www.biorxiv.org/content/10.64898/2026.10.15.759172v1
October 16, 2026 at 11:47 AM
Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1 https://www.biorxiv.org/content/10.64898/2026.10.15.759172v1
October 16, 2026 at 11:47 AM
Many underlying factors contributing to immunotherapy resistance remain unclear. Now published in the Oct 15 issue of JCI, we demonstrate that tumors amplified for NLRP3 drive the suppression of MHC class I antigen presentation and immune evasion. www.jci.org/articles/vie...
@jci.org
#NLRP3
JCI - Tumor NLRP3 amplification promotes immunotherapy resistance by inhibiting STAT1 signaling and MHC class I expression
www.jci.org
October 16, 2026 at 2:16 PM
What does this tell us about the ependyma as a neuroimmune interface?

In MS tissue, ependymal cells adjacent to periventricular damage adopt immune-reactive states, with STAT1/STAT3-associated signatures and junctional remodelling. /16
October 16, 2026 at 3:31 PM
snRNA-seq of human ependymal cells identified an MS-associated reactive state with dysregulated transporter and junction-associated genes.

By IHC, ependymal STAT1 was elevated beside gradient+ tissue, and AQP4 in MS ependyma irrespective of gradient status. /8
October 16, 2026 at 3:22 PM
Macrophages lacking INSIG1 worsen psoriasis via SREBP2-STAT1, with human lesions showing INSIG1 inversely linked to IL-23, IL-17A. Deeper insights into skin autoimmunity. PMID:42393041, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-73278-8 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis | Nature Communications
Psoriasis is an autoimmune skin disease, and its pathogenesis remains incompletely understood. As central drivers of psoriasis pathogenesis that bridge innate and adaptive immunity, macrophages are known to be modulated in their function by insulin-induced gene 1 (INSIG1), a regulator of cholesterol synthesis. Bioinformatic analysis of human psoriatic lesions reveals a significant negative correlation between INSIG1 expression and pro-inflammatory cytokine levels (IL-23, IL-17A). Single-cell RNA sequencing (scRNA-seq) and immunofluorescence confirm significantly reduced INSIG1 expression specifically in macrophages from psoriatic skin. In vivo, myeloid-specific Insig1 deficiency exacerbates imiquimod (IMQ)-induced psoriasiform dermatitis, characterized by increased epidermal thickening and immune infiltration. By activating sterol regulatory element-binding protein 2 (SREBP2), INSIG1 deficiency leads to the transcriptional upregulation of STAT1, which drives M1 macrophage polarization
doi.org
October 15, 2026 at 1:00 AM
The authors included RRIDs in their in Life Science Alliance paper! We value the author's support of reproducibility. #OpenResearch #methodsmatter #ReproducibleResearch
Dysferlin promotes inflammatory macrophage responses and modulates Ca2+-dependent STAT1 signaling
Read the full paper: Dysferlin promotes inflammatory macrophage responses and modulates Ca2+-dependent STAT1 signaling
doi.org
October 13, 2026 at 7:00 AM
Macrophage dysferlin regulates Ca²⁺-dependent STAT1-associated inflammatory responses and influences myogenic differentiation in cellular models. www.life-science-alliance.org/content/9/12...
October 11, 2026 at 3:04 PM
An important paper on the therapy of STAT1 GOF:
JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function rupress.org/jhi/article/...
JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function
Iglesias-Herrero et al. longitudinally assess JAK-inhibitor treatment response in two patients with STAT1 gain-of-function and show that it induces rapid b
rupress.org
October 9, 2026 at 7:06 PM
Iglesias-Herrero, Schrijvers et al. longitudinally assess JAK-inhibitor treatment response in two patients w/ #STAT1 gain-of-function & show that it induces rapid but incomplete immune reconstitution, w/ increased TCR diversity and reversal of monocyte hyperinflammation. rupress.org/jhi/article/...
October 9, 2026 at 5:00 PM